Abiopharma

180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

New Form 8-K - ArriVent BioPharma, Inc. Filed: 2025-08-11 AccNo: 0001558370-25-010974 Size: 367 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

XWELL, Inc. Regains Nasdaq Compliance

New Form SCHEDULE 13G - PERRIGO Co plc Filed: 2025-08-11 AccNo: 0000093751-25-000479 Size: 8 KB

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-08-11 AccNo: 0001171843-25-005266 Size: 14 KB